Multiple Myeloma
Multiple Myeloma
ClinicalActive
Key Facts
About Menarini
Menarini is a major, privately-held European pharmaceutical company with a diversified portfolio spanning pharmaceuticals, consumer healthcare, diagnostics, and derma-aesthetic medicine. It leverages a fully integrated model from R&D to global commercial execution, with a significant strategic focus on oncology and a strong partnering heritage. The company is actively investing in advanced science to build a pipeline for serious conditions while maintaining a core commitment to its values and corporate responsibility.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |